Neurocrine Biosciences, Inc. (NBIX) - NASDAQ
  • Thu, Feb. 11, 5:35 PM
    | Thu, Feb. 11, 5:35 PM
  • Oct. 8, 2015, 9:16 AM
    | Oct. 8, 2015, 9:16 AM | 2 Comments
  • Oct. 8, 2015, 8:13 AM
    • Neurocrine Biosciences (NASDAQ:NBIX) is up 22% premarket on light volume in response to its announcement of positive results in a Phase 3 clinical trial, Kinect 3, evaluating its VMAT2 inhibitor, NBI-98854, for the treatment of severe tardive dyskinesia in patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
    • Patients treated with 80 mg NBI-98854 showed a statistically significant change from baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 versus placebo as assessed by central blinded video raters. This was the primary efficacy endpoint. Specifically, the AIMS scores in the intent-to-treat population were reduced by an average of 3.1 points more than placebo (p<0.0001).
    • After completing its open-label safety studies, the company plans to file its NDA sometime in 2016.
    • VMAT2 (vesicular monoamine transporter 2) is a protein that transports monoamines (as the name suggests) such as the neurotransmitters dopamine, norepinephrine, serotonin and histamine. NBI-98854 is highly selective for regulating the levels of dopamine which reduces the chance of "off target" side effects.
    • Tardive dyskinesia is a neurological disorder characterized by repetitive and involuntary movements. It is caused by the long-term use of neuroleptic or anti-psychotic drugs. It occurs in ~20% of patients, more commonly in the elderly. There is no standard treatment for the condition.
    | Oct. 8, 2015, 8:13 AM
  • Jun. 9, 2015, 9:17 AM
    | Jun. 9, 2015, 9:17 AM | 5 Comments
  • Jun. 8, 2015, 5:37 PM
    | Jun. 8, 2015, 5:37 PM
  • Jan. 9, 2015, 5:35 PM
    | Jan. 9, 2015, 5:35 PM
  • Jan. 8, 2015, 12:47 PM
    | Jan. 8, 2015, 12:47 PM | 1 Comment
  • Jan. 8, 2015, 9:15 AM
    | Jan. 8, 2015, 9:15 AM
  • Jan. 8, 2015, 8:59 AM
    • Neurocrine Biosciences (NASDAQ:NBIX) jumps 25% premarket on higher-than-normal volume in response to collaboration partner AbbVie's (NYSE:ABBV) announcement of positive top-line results in a Phase 3 trial assessing the safety and efficacy of elagolix in premenopausal women with endometriosis. The study met its co-primary endpoints (p<0.001) of reducing scores of non-menstrual pelvic pain (NMPP) and menstrual pain associated with endometriosis at Month 3 as measured by the Daily Assessment of Endometriosis Pain scale.
    • Patients in the trial will continue in either post-treatment follow-up or a blinded six-month extension study. AbbVie plans to present the results at a future medical conference.
    • Neurocrine Bio and AbbVie entered into an exclusive worldwide collaboration agreement to commercialize elagolix in June 2010.
    | Jan. 8, 2015, 8:59 AM
  • Dec. 10, 2014, 5:39 PM
    • Top gainers, as of 5:15 p.m.: RH +5.8%. SFUN +5.2%. BXS +4.6%. AUQ +4.1%. AGI +3.2%.
    • Top losers, as of 5:15 p.m.: LAKE -9.4%. GDP -6.2%. BDC -4.7%. APT -3.9%. NBIX -3.6%.
    | Dec. 10, 2014, 5:39 PM
  • Jan. 8, 2014, 10:46 AM
    • Nomura's Ian Somaiya (formerly at Piper) is out with a number of healthcare initiations.
    • Gilead (GILD +1.7%) is the firm's top biotech pick for 2014 as the company is "set to dominate the HCV market." GILD started at Buy. Price target is $118.
    • Neurocrine Biosciences (NBIX -3.2%) started at Buy. Somaiya sees peak sales of $700M for NBI-98854. Price target is $23.
    • Celgene (CELG +1.2%) started at Buy. "Revlimid for multiple myeloma, is less than a third of the way to realizing its peak sales potential," Somaiya says. Price target is $236.
    • Biogen (BIIB +4.1%initiated at Buy. Tecfidera, is "a blockbuster ... treatment for MS, with estimated peak sales of $9B," Somaiya notes. Price target is $368.
    • Alexion (ALXN +1.5%) initiated at Buy. Price target $150.
    • Pharmacyclics (PCYC +1.9%) will "transform the treatment paradigm and disease course of CLL and mantle cell lymphoma MCL." Shares started at Buy. Price target is $137.
    • Other initiations: Incyte (INCY +5.9%started at Buy. Synageva BioPharma (GEVA +3.7%) started at Buy. BioMarin (BMRN +1.2%), Amgen (AMGN), and Infinity Pharmaceuticals (INFI +2.8%) started at Neutral.
    | Jan. 8, 2014, 10:46 AM | 2 Comments
  • Jan. 7, 2014, 3:49 PM
    • The rally in shares of Neurocrine Biosciences (NBIX +87.9%) that began Monday evening after the release of positive data from a study of NBI-98854, has gathered steam throughout the session.
    • The stock has nearly doubled on the day, helped by a CNBC appearance from the company's CEO.
    • For more, see SA Pro contributor Jason Napodano's new piece on the company (embargoed until 9:34 tomorrow).
    | Jan. 7, 2014, 3:49 PM
  • Jan. 7, 2014, 12:46 PM
    | Jan. 7, 2014, 12:46 PM | 1 Comment
  • Jan. 7, 2014, 9:16 AM
    | Jan. 7, 2014, 9:16 AM
  • Jan. 6, 2014, 4:09 PM
    • Neurocrine Biosciences (NBIX) jumps 43% AH as the company says the small molecule VMAT2 inhibitor NBI-98854 hit its primary endpoint in Kinect 2.
    • Week 6 AIMS scores: -2.6 points for the ITT group and -0.2 points for placebo — that's good for p<0.001.
    • Responder rate: 49% versus 18% in placebo for p<0.002.
    • "The profound response in this Kinect 2 study demonstrates the potential of NBI-98854 as both a safe and highly effective treatment for patients suffering from tardive dyskinesia," the company notes.
    • NBIX will now finalize the initial draft for Phase 3 protocol which it expects to file in H1. (PR)
    | Jan. 6, 2014, 4:09 PM
  • Sep. 10, 2013, 3:40 PM
    • Jefferies joins Deutsche Bank and Morgan Stanley in shrugging off Neurocrine Biosciences' (NBIX -29.4%) Phase 2 NBI-98854 setback.
    • Analyst Thomas Wei points to the apparently efficacious 100mg dose, although he does conceded that the failure "raises the risk profile around the drug."
    • Wei nevertheless maintains a Buy rating and a $16 price target, as '854 is written-off as "upside to valuation."
    | Sep. 10, 2013, 3:40 PM
Company Description
Neurocrine Biosciences, Inc. operates as a product based biopharmaceutical company, which discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January... More
Sector: Healthcare
Industry: Biotechnology
Country: United States